Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 2,275 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| NRX Pharmaceuticals Inc | NRXP | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.15 | 4.92% | 3.20 | 08:04:02 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 3.05 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 16 | 2,275 | - | 2.21 - 12.00 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 08:04:06 | 2 | $ 3.20 | USD |
NRX Pharmaceuticals Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 255.95M | 83.92M | - | 0 | -30.16M | -0.36 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
NRX Pharmaceuticals News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical NRXP Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 4.26 | 4.30 | 2.7201 | 3.12 | 288,885 | -1.06 | -24.88% |
| 1 Month | 5.293 | 6.00 | 2.7201 | 4.72 | 482,143 | -2.09 | -39.54% |
| 3 Months | 3.90 | 7.333 | 2.7201 | 5.11 | 1,506,088 | -0.70 | -17.95% |
| 6 Months | 2.789 | 7.333 | 2.603 | 4.70 | 1,145,377 | 0.411 | 14.74% |
| 1 Year | 5.70 | 12.00 | 2.21 | 4.20 | 1,026,935 | -2.50 | -43.86% |
| 3 Years | 230.10 | 262.40 | 2.21 | 69.35 | 1,613,479 | -226.90 | -98.61% |
| 5 Years | 230.10 | 262.40 | 2.21 | 69.35 | 1,613,479 | -226.90 | -98.61% |
NRX Pharmaceuticals Description
| NRX Pharmaceuticals Inc is a clinical-stage, small molecule pharmaceutical company which develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. It is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behaviour. |
